Molecular Therapy - Nucleic Acids

Slides:



Advertisements
Similar presentations
Molecular Therapy - Nucleic Acids
Advertisements

Targeted Disruption of V600E-Mutant BRAF Gene by CRISPR-Cpf1
Expanding the Biologist’s Toolkit with CRISPR-Cas9
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Matan Goldshtein, David B. Lukatsky  Biophysical Journal 
Oligonucleotide Delivery to the Lung: Waiting to Inhale
A Method to Evaluate the Quality of Clinical Gene-Panel Sequencing Data for Single- Nucleotide Variant Detection  Chung Lee, Joon S. Bae, Gyu H. Ryu, Nayoung.
Genome-editing Technologies for Gene and Cell Therapy
Figure 2 Use of CRISPR/Cas9 for genome editing
162. Stability of Polymer/Plasmid DNA Complexes In Vitro and In Vivo
Volume 10, Issue 3, Pages (March 2017)
Molecular Therapy - Nucleic Acids
N6-Methyladenosines Modulate A-to-I RNA Editing
CRISPR-Cas Systems: Prokaryotes Upgrade to Adaptive Immunity
Research Techniques Made Simple: The Application of CRISPR-Cas9 and Genome Editing in Investigative Dermatology  Joan Ramon Guitart, Jodi L. Johnson,
Nicolas Erard, Simon R.V. Knott, Gregory J. Hannon  Molecular Cell 
Target-Specific Precision of CRISPR-Mediated Genome Editing
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Choosing the Right Tool for the Job: RNAi, TALEN, or CRISPR
Haiyan Dong, Ji Ma, Jie Wang, Zai-Sheng Wu, Patrick J Sinko, Lee Jia 
CRISPR-Cas9 for in vivo Gene Therapy: Promise and Hurdles
Therapeutic editing of hepatocyte genome in vivo
USH2A Gene Editing Using the CRISPR System
CRISPR genome-editing: A medical revolution
Technical Validation of a Next-Generation Sequencing Assay for Detecting Clinically Relevant Levels of Breast Cancer–Related Single-Nucleotide Variants.
Jan Hoinka, Phuong Dao, Teresa M Przytycka 
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Xiaoyu Chen, Jin Liu, Josephine M. Janssen, Manuel A.F.V. Gonçalves 
Volume 154, Issue 6, Pages (September 2013)
IRNA-PseColl: Identifying the Occurrence Sites of Different RNA Modifications by Incorporating Collective Effects of Nucleotides into PseKNC  Pengmian.
Current Progress in Therapeutic Gene Editing for Monogenic Diseases
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
Genome-editing Technologies for Gene and Cell Therapy
Toward Whole-Transcriptome Editing with CRISPR-Cas9
High-Throughput Identification and Quantification of Candida Species Using High Resolution Derivative Melt Analysis of Panfungal Amplicons  Tasneem Mandviwala,
Gang Wang, Na Zhao, Ben Berkhout, Atze T Das  Molecular Therapy 
GFP to BFP Conversion: A Versatile Assay for the Quantification of CRISPR/Cas9- mediated Genome Editing  Astrid Glaser, Bradley McColl, Jim Vadolas  Molecular.
Volume 11, Issue 6, Pages (May 2015)
Designer Lipids Advance Systemic siRNA Delivery
Zhao Zhang, Yuelin Zhang, Fei Gao, Shuo Han, Kathryn S
Volume 25, Issue 1, Pages (January 2017)
Genome Editing Technologies: Defining a Path to Clinic
At Last: Gene Editing in Human Embryos to Understand Human Development
521. Multiplex Genome Editing of TCR°/CD52 Genes as a Platform for “Off the Shelf” Adoptive T-Cell Immunotherapies    Molecular Therapy  Volume 22, Pages.
A CRISPR Approach to Gene Targeting
William T. Hendriks, Curtis R. Warren, Chad A. Cowan  Cell Stem Cell 
Molecular Therapy - Nucleic Acids
Volume 8, Issue 11, Pages (November 2015)
Ignazio Maggio, Manuel A.F.V. Gonçalves  Trends in Biotechnology 
Molecular Therapy - Nucleic Acids
iRNA-PseU: Identifying RNA pseudouridine sites
Molecular Therapy - Nucleic Acids
Volume 23, Issue 3, Pages (March 2015)
Fiona T van den Berg, John J Rossi, Patrick Arbuthnot, Marc S Weinberg 
372. Targeted Mutagenesis of Ubiquitin-Binding Lysine Residues on the Adeno- Associated Virus (AAV)2 Capsid Improves Its Transduction Efficiency    Molecular.
Ciaran M Lee, Thomas J Cradick, Gang Bao  Molecular Therapy 
Volume 16, Issue 2, Pages (February 2015)
Molecular Therapy - Nucleic Acids
Molecular Therapy - Nucleic Acids
Thomas J Cradick, Peng Qiu, Ciaran M Lee, Eli J Fine, Gang Bao 
Volume 4, Issue 2, Pages e4 (February 2017)
Molecular Therapy - Nucleic Acids
Xing Hua, Haiming Xu, Yaning Yang, Jun Zhu, Pengyuan Liu, Yan Lu 
Molecular Therapy - Nucleic Acids
Off-target Effects in CRISPR/Cas9-mediated Genome Engineering
Nuclease Target Site Selection for Maximizing On-target Activity and Minimizing Off- target Effects in Genome Editing  Ciaran M Lee, Thomas J Cradick,
Development of a Novel Next-Generation Sequencing Assay for Carrier Screening in Old Order Amish and Mennonite Populations of Pennsylvania  Erin L. Crowgey,
CRISPR Craze to Transform Cardiac Biology
Presentation transcript:

Molecular Therapy - Nucleic Acids Deciphering relationship between microhomology and in-frame mutation occurrence in human CRISPR-based gene knockout  Guohui Chuai, Fayu Yang, Jifang Yan, Yanan Chen, Qin Ma, Chi Zhou, Chenyu Zhu, Feng Gu, Qi Liu  Molecular Therapy - Nucleic Acids  Volume 5, (January 2016) DOI: 10.1038/mtna.2016.35 Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions

Figure 1 The analyzing pipeline and corresponding microhomology pattern analysis results. (a) A computational pipeline CAGE for the analysis of CRISPR-Cas9 knock-out next-generation sequencing (NGS) data; (b) The sgRNA-Indel table generated by our pipeline; (c) An illustration of the microhomology pattern detected in the NGS data; (d) Comparisons of the Pearson coefficient calculated as the out-of-frame score correlated to the frequencies of the out-of-frame shifting reads among the indel reads, with that of the out-of-frame score correlated to out-of-frame shifting reads among all sequence reads, for one TALEN and two REGN datasets respectively1; (e) Contingency table analysis for the 68 sgRNAs in Hela cell, showing that for all the 68 sgRNAs, no significant correlations between the frameshifting paradigm and microhomology exist; (f) An illustration of the selected genomics features that influence the OTF ratio prediction. Given the notable difference in the prediction performance of the model using genomic features and epigenetic features, we assume that the epigenetic features mainly affect the affinity between the CRISPR-Cas9 complex and chromatin. This may serve as a precondition to trigger the nonhomologous end-joining (NHEJ) pathway to generate indels. Therefore, epigenetic features may not be an appropriate influence factors on sgRNA KO out-of-frame mutation occurrence rate, because epigenetic features correlate more with the sgRNA binding affinity than with out-of-frame mutations. On the other hand, we propose that genomic features mainly affect the eventual in-frame mutations of the CRISPR-Cas9 KO system by nucleotide pairings when the chromatins are open, because NHEJ is easily triggered in this case. Such sequence determining factors can be learned from the CRISPR-based sgRNA KO data. In summary, we present a learning-based model to predict the out-of-frame mutation occurrence rate to raise our concerns regarding the microhomology-based choice of target sites. Notably, although the current training number of sgRNAs is relatively small, our pipeline can incorporate more samples when more CRISPR-based KO sequencing data emerge. In the current study, we witnessed from limited data that the relationship between micohomology profile and in-frame mutation occurrence is needed to be carefully investigated, and the current conclusions are drawn on specific cell types. The accumulation and analysis of more data will allow for the identification of more representative sequence determinants for improved on-target sgRNA design for different cell type or organism. We hope our study will make useful complementary to the study pioneered by Sangsu Bae et al., lead to increased efforts to clarify the DNA double-strand break repairing mechanism, and provide novel clues for efficient sgRNA design to reduce in-frame mutations. Avaliability: We established CAGE (CRISPR KO Analysis based on Genomic Editing data), a CRISPR-cas9-based genome editing data analysis pipeline, for the analysis of indels and microhomology patterns from CRISPR-Cas9 knock-out NGS data and evaluation of sgRNA KO efficiency. CAGE is available at https://github.com/bm2-lab/cage. Molecular Therapy - Nucleic Acids 2016 5, DOI: (10.1038/mtna.2016.35) Copyright © 2016 Official journal of the American Society of Gene & Cell Therapy Terms and Conditions